Shuqing Liu

Shuqing Liu


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2012 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
CGChunmei Guo
Chunmei Guo
SLShuqing Liu
Shuqing Liu
MSMing-Zhong Sun
Ming-Zhong Sun

24 July 2012 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
XZXiaohui Zhang
Xiaohui Zhang
SLShuqing Liu
Shuqing Liu
CGChunmei Guo
Chunmei Guo
JZJunwei Zong
Junwei Zong
MSMing-Zhong Sun
Ming-Zhong Sun

1 March 2021 in NeuroToxicology
Verified
Journal Article
Closed access
KWKe Wang
Ke Wang
YSYongquan Shi
Yongquan Shi
WLWei Liu
Wei Liu
SLShuqing Liu
Shuqing Liu
MSmingzhong sun
mingzhong sun

5 February 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CGChunmei Guo
Chunmei Guo
DZDongting Zhao
Dongting Zhao
QZQiuling Zhang
Qiuling Zhang
SLShuqing Liu
Shuqing Liu
MSmingzhong sun
mingzhong sun
Tumor metastasis is one of the main causes of hepatocellular carcinoma (HCC) high mortality. CRKL (v-crk sarcoma virus CT10 oncogene homologue (avian)-like) play important roles in tumor metastasis, however, the exact role and underlying mechanism of CRKL in HCC is still unknown. In our study, we demonstrated miR-429 negatively regulated CRKL expression via selectively binding to CRKL-3′-UTR at 3728–3735 bp site by post-transcriptionally mediating its functionality. Re-expression and silencing of miR-429 was remarkably effective in suppressing and promoting HepG2 cell migration and invasion in vitro. Knockdown or overexpression of CRKL exhibited similar effects as the overexpression or silencing of miR-429, whereas, CRKL overexpression (without the 3′-UTR) abrogated miR-429-induced inhibition on HepG2 migration and invasion. Moreover, miR-429-CRKL axis affected HepG2 migration and invasion potentials by regulating the adhesion ability, cytoskeleton F-actin expression and arrangement of HepG2. Furthermore, interference of Raf/MEK/ERK pathway and EMT contributed to miR-429-CRKL axis mediated metastasis inhibition. Nevertheless, miR-429 could not inhibit HepG2 proliferation through CRKL/c-Jun pathway. Taken together, our data demonstrated that miR-429 might function as an antimetastatic miRNA to regulate HCC metastasis by directly targeting CRKL via modulating Raf/MEK/ERK-EMT pathway. The newly identified miR-429-CRKL axis represents a novel potential therapeutic target for HCC treatment.

20 April 2021 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
QLQian Li
Qian Li
SLShuqing Liu
Shuqing Liu
JYJinsong Yan
Jinsong Yan
MSmingzhong sun
mingzhong sun
FGFrederick T. Greenaway
Frederick T. Greenaway

1 July 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JWJinxia Wang
Jinxia Wang
CWChengyi Wang
Chengyi Wang
QLQian Li
Qian Li
CGChunmei Guo
Chunmei Guo
WSWeibin Sun
Weibin Sun
MSmingzhong sun
mingzhong sun
The pathogenesis and tumorigenesis of clear cell renal cell carcinoma (ccRCC) remain unclear. The deregulations of miR-429, a member of miR-200 family, and v-crk sarcoma virus CT10 oncogene homologue (avian)-like (CRKL), an adaptor protein of CRK family, are involved in the development, metastasis and prognosis of various cancers. Current study aimed to demonstrate the differential expressions of miR-429 and CRKL with their correlationship and molecular regulation mechanism in ccRCC malignancy. miR-429 and CRKL separately showed suppressing and promoting effects in ccRCC. Lower miR-429 expression and higher CRKL expression were negatively correlated in surgical cancerous tissues by promoting the advance of ccRCC. By binding to the 3'-UTR of CRKL, miR-429 reversely regulated CRKL for its functionalities in ccRCC cells. CRKL knockdown and overexpression separately decreased and increased the in vitro migration and invasion of 786-O cells, which were consistent with the influences of miR-429 overexpression and knockdown on 786-O through respectively downregulating and upregulating CRKL via SOS1/MEK/ERK/MMP2/MMP9 pathway. The enhancements of CRKL expression, migration and invasion abilities and SOS1/MEK/ ERK/MMP2/MMP9 activation induced by TGF-β stimulation in 786-O cells could be antagonized by miR-429 overexpression. Exogenous re-expression of CRKL abrogated miR-429 suppression on the migration and invasion of 786-O cells. Collectively, miR-429 deficiency negatively correlated with CRKL overexpression promoted the aggressiveness of cancer cells and advanced the clinical progression of ccRCC patients. miR-429-CRKL axial regulation provides new clues to the fundamental research, diagnosis and treatment of ccRCC.